<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-11100R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0008285</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders</subject><subject>Oncology</subject><subject>Cell Biology/Cell Signaling</subject></subj-group></article-categories><title-group><article-title>A Phosphoinositide 3-Kinase/Phospholipase Cgamma1 Pathway Regulates Fibroblast Growth Factor-Induced Capillary Tube Formation</article-title><alt-title alt-title-type="running-head">PI3K/PLC&#x003b3;1 in FGF Signalling</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maffucci</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Raimondi</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abu-Hayyeh</surname><given-names>Shadi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dominguez</surname><given-names>Veronica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sala</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zachary</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Falasca</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Medicine, British Heart Foundation Laboratories, Centre for Cardiovascular Biology and Medicine, University College London, London, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Hotchin</surname><given-names>Neil A.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Birmingham, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>m.falasca@qmul.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TM IZ MF. Performed the experiments: TM CR SAH VD GS MF. Analyzed the data: TM IZ MF. Wrote the paper: TM MF.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2009</year></pub-date><volume>4</volume><issue>12</issue><elocation-id>e8285</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>Maffucci et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>The fibroblast growth factors (FGFs) are key regulators of embryonic development, tissue homeostasis and tumour angiogenesis. Binding of FGFs to their receptor(s) results in activation of several intracellular signalling cascades including phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC)&#x003b3;1. Here we investigated the basic FGF (FGF-2)-mediated activation of these enzymes in human umbilical vein endothelial cells (HUVECs) and defined their role in FGF-2-dependent cellular functions.</p></sec><sec><title>Methodology/Principal Findings</title><p>We show that FGF-2 activates PLC&#x003b3;1 in HUVECs measured by analysis of total inositol phosphates production upon metabolic labelling of cells and intracellular calcium increase. We further demonstrate that FGF-2 activates PI3K, assessed by analysing accumulation of its lipid product phosphatidylinositol-3,4,5-P<sub>3</sub> using TLC and confocal microscopy analysis. PI3K activity is required for FGF-2-induced PLC&#x003b3;1 activation and the PI3K/PLC&#x003b3;1 pathway is involved in FGF-2-dependent cell migration, determined using Transwell assay, and in FGF-2-induced capillary tube formation (tubulogenesis assays <italic>in vitro</italic>). Finally we show that PI3K-dependent PLC&#x003b3;1 activation regulates FGF-2-mediated phosphorylation of Akt at its residue Ser473, determined by Western blotting analysis. This occurs through protein kinase C (PKC)&#x003b1; activation since dowregulation of PKC&#x003b1; expression using specific siRNA or blockade of its activity using chemical inhibition affects the FGF-2-dependent Ser473 Akt phosphorylation. Furthermore inhibition of PKC&#x003b1; blocks FGF-2-dependent cell migration.</p></sec><sec><title>Conclusion/Significance</title><p>These data elucidate the role of PLC&#x003b3;1 in FGF-2 signalling in HUVECs demonstrating its key role in FGF-2-dependent tubulogenesis. Furthermore these data unveil a novel role for PLC&#x003b3;1 as a mediator of PI3K-dependent Akt activation and as a novel key regulator of different Akt-dependent processes.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Angiogenesis, the formation of new vessels from existing vasculature, is required for different physiological processes such as development, reproduction, wound healing, and tissue regeneration <xref ref-type="bibr" rid="pone.0008285-Carmeliet1">&#x0005b;1&#x0005d;</xref>. On the other hand angiogenesis is involved in pathologies such as arteriosclerosis, diabetic retinopathy, rheumatoid arthritis and tumour growth <xref ref-type="bibr" rid="pone.0008285-Risau1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Ferrara1">&#x0005b;3&#x0005d;</xref>. Angiogenesis consists of a multistep process involving capillary endothelial cell (EC) migration and proliferation and the formation of three-dimensional structures capable of carrying blood <xref ref-type="bibr" rid="pone.0008285-Carmeliet1">&#x0005b;1&#x0005d;</xref>. A complex network of growth factors and cytokines regulates angiogenesis including the family of vascular endothelial growth factor (VEGFs) and fibroblast growth factor (FGFs) <xref ref-type="bibr" rid="pone.0008285-CrossM1">&#x0005b;4&#x0005d;</xref>. The signalling pathways activated by VEGFs have been extensively investigated in physiological and pathological angiogenesis. For instance the key role of VEGFs in tumour angiogenesis is well recognised <xref ref-type="bibr" rid="pone.0008285-Carmeliet2">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Ferrara2">&#x0005b;6&#x0005d;</xref> and several anti-angiogenic agents targeting VEGFs signalling are now available for anti-cancer strategy. The FGFs family consists of at least 22 factors that play a crucial role in morphogenesis during embryo development and in control of the nervous system, tissue repair and wound healing in the adult organism <xref ref-type="bibr" rid="pone.0008285-Eswarakumar1">&#x0005b;7&#x0005d;</xref>. On the other hand, several lines of evidence indicate that FGFs, in particular FGF-2, play a key role in tumour angiogenesis <xref ref-type="bibr" rid="pone.0008285-Cao1">&#x0005b;8&#x0005d;</xref>. For instance FGF-2 is frequently highly expressed in highly vascularized and advanced cancers <xref ref-type="bibr" rid="pone.0008285-Soutter1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0008285-Nguyen1">&#x0005b;11&#x0005d;</xref> and it has been reported that a synergistic action of FGF-2 and platelet derived growth factor-BB promotes tumour angiogenesis and pulmonary metastasis in mice <xref ref-type="bibr" rid="pone.0008285-Cao1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Nissen1">&#x0005b;12&#x0005d;</xref>. In addition FGF-2 has been shown to be associated with resistance to anti-VEGF agents <xref ref-type="bibr" rid="pone.0008285-Casanovas1">&#x0005b;13&#x0005d;</xref>. Germline mutations in FGF receptors have been detected in different cancer types <xref ref-type="bibr" rid="pone.0008285-Beenken1">&#x0005b;14&#x0005d;</xref> and data suggest that inhibitions of these receptors through small molecule inhibitors or antibodies may be of clinical value <xref ref-type="bibr" rid="pone.0008285-Beenken1">&#x0005b;14&#x0005d;</xref>.</p><p>Binding of VEGFs and FGFs to their respective receptors leads to receptor phosphorylation and subsequent activation of signalling proteins including the Ras pathway, the Src family tyrosine kinases, phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC)&#x003b3;1.</p><p>PI3Ks are a conserved family of lipid kinases that catalyze the phosphorylation of the D3 position of the inositol ring of phosphoinositides at the plasma membrane or in specific cellular membrane compartments. Interaction between the newly generated 3-phosphorylated phosphoinositides and distinct structural motifs, such as pleckstrin homology (PH) domain, can regulate the activity of different proteins through their membrane targeting or direct modulation of their enzymatic activity <xref ref-type="bibr" rid="pone.0008285-Maffucci1">&#x0005b;15&#x0005d;</xref>. Among such proteins the serine/threonine kinase protein kinase B (PKB)/Akt, an enzyme involved in diverse intracellular events including cell proliferation, migration, survival and cell cycle progression, is undoubtedly the most studied and best characterised. Several lines of evidence indicate that PI3K plays an important role in VEGF signalling, angiogenesis and regulation of VEGF expression <xref ref-type="bibr" rid="pone.0008285-Jiang1">&#x0005b;16&#x0005d;</xref>. While the VEGF-dependent activation of PI3K has been extensively studied, the mechanism of FGF-mediated activation of PI3K has been controversial until few years ago when it was demonstrated that a growth factor-induced coordinated assembly of a multi-docking protein complex is necessary for the FGF-2-mediated activation of PI3K <xref ref-type="bibr" rid="pone.0008285-Ong1">&#x0005b;17&#x0005d;</xref>.</p><p>PLC&#x003b3;1 hydrolyzes phosphatidylinositol-4,5-bisphosphate to generate the second messengers inositol-1,4,5-trisphosphate and diacylglycerol which in turn can activate several downstream effectors including specific protein kinase C (PKC) isoforms leading to many cellular responses <xref ref-type="bibr" rid="pone.0008285-Divecha1">&#x0005b;18&#x0005d;</xref>. Several lines of evidence indicate that PLC&#x003b3;1 plays a critical role in angiogenesis, especially in VEGF signalling with data suggesting a role for this enzyme in mediating VEGF-induced cell proliferation and others revealing a role for PLC&#x003b3;1 in stimulating VEGF-induced differentiation and tubulogenesis <xref ref-type="bibr" rid="pone.0008285-Rahimi1">&#x0005b;19&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0008285-Meyer1">&#x0005b;21&#x0005d;</xref>. PLC&#x003b3;1 deletion results in reduced vasculogenesis and erythropoiesis in mice <xref ref-type="bibr" rid="pone.0008285-Liao1">&#x0005b;22&#x0005d;</xref> and in defects in artery formation in transgenic zebrafish models <xref ref-type="bibr" rid="pone.0008285-Lawson1">&#x0005b;23&#x0005d;</xref>. The role of PLC&#x003b3;1 in FGF signalling has been less investigated. Although the general mechanism of PLC&#x003b3;1 activation involves its receptor-mediated tyrosine phosphorylation, we demonstrated that PLC&#x003b3;1 can also be activated downstream to PI3K in a mechanism involving the interaction between its PH domain and the PI3K product phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P<sub>3</sub>) <xref ref-type="bibr" rid="pone.0008285-Falasca1">&#x0005b;24&#x0005d;</xref>.</p><p>Here we show that FGF-2 activates PLC&#x003b3;1 in human umbilical vein endothelial cells (HUVECs) and that this enzyme is critical for the FGF-2-dependent cell migration and capillary tube formation (angiogenesis <italic>in vitro</italic>). Moreover our data demonstrate that a PI3K-dependent PLC&#x003b3;1 activation regulates FGF-2-mediated phosphorylation of Akt through PKC&#x003b1; activation, unveiling a novel role for PLC&#x003b3;1 as a mediator of the PI3K-dependent Akt activation and as a key regulator of different Akt-dependent processes.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="s2a"><title>Materials</title><p>FGF-2 and VEGF were purchased from Peprotech, siGENOME smartpool for PLC&#x003b3;1, PLC&#x003b3;2 and PKC&#x003b1; from Dharmacon; scrambled siRNA from Ambion; U73122, U73343, LY294002, G&#x000f6;6976, PD98059 and U0126 from Calbiochem; SH5 from Alexis Biochemicals; wortmannin from Sigma. Alternative siRNA targeting PLC&#x003b3;2 was purchased from Qiagen. Anti PtdIns-3,4,5-P<sub>3</sub> was purchased from Echelon, anti PLC&#x003b3;1, anti Akt, anti actin, anti PLC&#x003b3;2, anti ERK2, anti PKC&#x003b1; from Santa Cruz Biotechnology; anti pSer473 Akt from Cell Signaling Technology.</p></sec><sec id="s2b"><title>Cell lines and cultures</title><p>HUVEC were purchased from TCS CellWorks and grown in EGM kit (EBM&#x0002b;singlequots, Lonza) supplemented with 10&#x00025; FBS. For expression of GFP-PH PLC&#x003b3;1, HUVEC were electroporated as described <xref ref-type="bibr" rid="pone.0008285-Ear1">&#x0005b;25&#x0005d;</xref>. Briefly, cells detached from a 10-cm cell culture dish were resuspended in 400 &#x000b5;l of electroporation buffer (20 mM Hepes pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub>HPO<sub>4</sub>, 6 mM D-glucose) and incubated with 25 &#x000b5;g DNA in a cuvette for 10 min at room temperature. Cells were electroporated (960 &#x000b5;F, 200 V) by using a Bio-Rad Gene Pulser instrument (time constant &#x0223c;26 sec) and then left in the cuvette for a further 10 min at room temperature before plating.</p><p>For siRNA-based experiments, confluent HUVEC plated in 6 well plates were transfected by incubating in OPTIMEM containing oligofectAMINE (Invitrogen) and 200 nM siRNA. After 24 h cells were serum starved overnight in M199&#x0002b;0.5&#x00025; FBS before being used for experiments. Alternatively, number of cells was determined 24 h or 48 h after transfection by manual counting.</p></sec><sec id="s2c"><title>Inositol phosphates production</title><p>Cells were labelled with &#x0005b;<sup>3</sup>H&#x0005d;<italic>myo</italic> inositol (PerkinElmer) in inositol free medium M199 supplemented with 2&#x00025; FBS. After 24 h, cells were incubated in M199 containing 10 mM Hepes and 20 mM LiCl for 15 min before stimulation, then lysed in 0.1 M HCOOH. Total inositol phosphates were separated by anion exchange chromatography by using AG 1-X8 resin (formate form, 200&#x02013;400 mesh, BioRad) and the total amount assessed by liquid radioactivity counting.</p></sec><sec id="s2d"><title>PI3K activation in vivo</title><p>PtdIns-3,4,5-P<sub>3</sub> production was assessed by thin layer chromatography (TLC) analysis as described <xref ref-type="bibr" rid="pone.0008285-Maffucci2">&#x0005b;26&#x0005d;</xref>. Briefly, cells grown in a 6 well plate were incubated with 0.8 mCi/well &#x0005b;<sup>32</sup>P&#x0005d;phosphoric acid (PerkinElmer) in phosphate free medium M3786 (Sigma) for 3 h before stimulation as indicated. Phospholipids were extracted, dried under nitrogen, resuspended in 100 &#x000b5;l chloroform&#x02236;methanol (3&#x02236;2) and spotted onto silica plates pre-soaked in water&#x02236;methanol (3&#x02236;2) containing 1.2&#x00025; (w/v) oxalic acid and oven baked for 15 min at 110&#x000b0;C. TLC plates were developed in chloroform: acetone: methanol: acetic acid: water (90&#x02236;36&#x02236;30&#x02236;27&#x02236;18).</p></sec><sec id="s2e"><title>Migration and Tubulogenesis assay in vitro</title><p>Assays of cell migration were performed by using Transwell chambers (10 mm diameter, 8 &#x000b5;m pores, Costar Corp.) as described <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref>. Capillary tube formation was performed as described on growth factor-reduced Matrigel <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref>.</p></sec><sec id="s2f"><title>Confocal microscopy analysis</title><p>Microscopy was performed by using a Zeiss laser confocal microscope system (LSM 510) connected to an Axiovert 100M (Zeiss) and a Zeiss 63X objective. Images were acquired and loaded by using a TCS NT program (version 1.6.587). No further processing of the images was done except for changes in brightness/contrast to better visualize the data. Images were collected at 3.5 &#x000b5;m from the bottom and all conditions were imaged at the same distance from the glass.</p></sec><sec id="s2g"><title>Calcium measurement assay</title><p>Changes in intracellular calcium were determined using the fluorescent calcium indicator Fluo-4 AM (Invitrogen). Cells were seeded on Lab-Tek chambered #1.0 borosilicate coverglass (LABTEK) for confocal live microscopy and serum starved overnight. Each well was then incubated with 200 &#x000b5;l of HBSS containing 0.5&#x00025; BSA, 2 mM CaCl<sub>2,</sub> 4 &#x000b5;M Fluo-4 for 45 min at 37&#x000b0;C. Cells were then washed twice with HBSS containing 0.5&#x00025; BSA, 2 mM CaCl<sub>2</sub> and incubated at 37&#x000b0;C in the same solution for 30 min to allow de-esterification of Fluo-4. Where indicated, 10 &#x000b5;M LY29400 was added after the first 15 minutes of the de-esterification passage for 15 min. Samples were analyzed using the Zeiss confocal microscope LSM 510 equipped with a chamber for live imaging at 37&#x000b0;C supplied with 5&#x00025; CO<sub>2</sub> using a 10X objective. After recording basal fluorescent, cells were stimulated with 100 ng/ml FGF-2 in the presence or in the absence of 10 &#x000b5;M LY294002 and fluorescence was measured for 10 min. At the end of each experiment, cells were stimulated with 1 mM ATP. ZEN Carl Zeiss software was used for acquisition and analysis of raw data. Fluorescence values of 40 cells per chamber were analyzed and expressed as mean of fluorescence.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>FGF-2 activates PLC&#x003b3;1 in ECs</title><p>In order to determine whether PLC&#x003b3;1 is a downstream target of FGF-2 in HUVEC we monitored the activation of the enzyme by metabolic labelling of cells and analysis of the total amount of inositol phosphates generated upon FGF-2 stimulation. Our data show that FGF-2 increased the levels of inositol phosphates in &#x0005b;<sup>3</sup>H&#x0005d;-labelled HUVEC (<xref ref-type="fig" rid="pone-0008285-g001">Figure 1A</xref>) and induced Ca<sup>2&#x0002b;</sup> release from intracellular stores (<xref ref-type="fig" rid="pone-0008285-g001">Figure 1B</xref>), indicating activation of a PLC isoform. Downregulation of PLC&#x003b3;1 expression using specific siRNA significantly reduced the FGF-2-dependent production of inositol phosphates, indicating that this isoform is specifically activated upon FGF-2 stimulation (<xref ref-type="fig" rid="pone-0008285-g001">Figure 1A</xref>). No reduction on the expression levels of the related PLC isoform PLC&#x003b3;2 was observed in HUVEC transfected with the specific siRNA targeting PLC&#x003b3;1 (<xref ref-type="fig" rid="pone-0008285-g001">Figure 1C</xref>). Interestingly, while PLC&#x003b3;1 downregulation did not reduce the number of cells compared to HUVEC transfected with a control scrambled siRNA, expression of a specific siRNA targeting PLC&#x003b3;2 strongly reduced the number of cells after 24 h or 48 h from transfection (<xref ref-type="fig" rid="pone-0008285-g001">Figure 1D</xref>). Similar results were obtained using a distinct siRNA targeting PLC&#x003b3;2 (<xref ref-type="supplementary-material" rid="pone.0008285.s001">Figure S1</xref>). These data clearly indicate that PLC&#x003b3;1 and PLC&#x003b3;2 play distinct roles in HUVEC, with PLC&#x003b3;2 but not PLC&#x003b3;1 being possibly involved in proliferation and/or survival of cells.</p><fig id="pone-0008285-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g001</object-id><label>Figure 1</label><caption><title>FGF-2 activates PLC&#x003b3;1 in ECs.</title><p>(A) HUVEC were transfected with scrambled siRNA or specific siRNA to downregulate PLC&#x003b3;1 expression. After 24 h cells were labelled with &#x0005b;<sup>3</sup>H&#x0005d;myo inositol in M199 containing 2&#x00025; FBS for a further 24 h and then stimulated with 100 ng/ml FGF-2 for the indicated times. Data indicate the total amount of inositol phosphates generated at the indicated times and are expressed as percentage of the basal inositol phosphates. Data are means&#x000b1;SEM of values obtained from 5 independent experiments. &#x0002a;p&#x0003c;0.05, &#x0002a;&#x0002a;p&#x0003c;0.01. Blot shows PLC&#x003b3;1 expression in lysates of HUVEC transfected with a control scrambled siRNA or siRNA targeting PLC&#x003b3;1. Equal loading of proteins was assessed by using an anti actin antibody. (B) Intracellular calcium increase in serum starved HUVEC was determined as described in the <xref ref-type="sec" rid="s2">Materials and Methods</xref> session. Cells were stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times (arrows). Data are mean of values obtained from 4 independent experiments. (C) Expression levels of PLC&#x003b3;1 or PLC&#x003b3;2 in HUVEC transfected with the indicated siRNAs. Equal loading was confirmed using anti Akt or anti ERK antibodies. (D) HUVEC were transfected with scrambled siRNA or siRNAs targeting PLC&#x003b3;1 or PLC&#x003b3;2. The number of cells was determined by manual counting 24 h or 48 h after transfection. Data are expressed as percentage of cells transfected with scrambled siRNA at each time point and are means&#x000b1;SEM of values obtained from 6 independent experiments. &#x0002a;p&#x0003c;0.05, &#x0002a;&#x0002a;p&#x0003c;0.01 vs HUVEC expressing siRNA PLC&#x003b3;1. In C and D siRNA targeting PLC&#x003b3;2 were from Dharmacon.</p></caption><graphic xlink:href="pone.0008285.g001"/></fig></sec><sec id="s3b"><title>FGF-2-dependent PLC&#x003b3;1 activation requires PI3K</title><p>In an effort to define the mechanism of FGF-2-induced PLC&#x003b3;1 activation, we found that pre-treatment of cells with the reversible PI3K inhibitor LY294002 significantly inhibited the FGF-2-induced inositol phosphates production (<xref ref-type="fig" rid="pone-0008285-g002">Figure 2A</xref>). Similar results were obtained using the irreversible PI3K inhibitor wortmannin (<xref ref-type="supplementary-material" rid="pone.0008285.s002">Figure S2</xref>). Pre-treatment of cells with LY294002 completely blocked FGF-2-induced intracellular calcium increase without affecting the ATP-mediated release (<xref ref-type="fig" rid="pone-0008285-g002">Figure 2B</xref>). These data indicate that PI3K is required for full activation of PLC&#x003b3;1, consistent with evidence indicating that PI3K can have a role in PLC&#x003b3;1 activation <xref ref-type="bibr" rid="pone.0008285-Falasca1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Maffucci4">&#x0005b;28&#x0005d;</xref>. In addition we observed that the isolated N-terminal PH domain of PLC&#x003b3;1 fused to green fluorescent protein (GFP-PH PLC&#x003b3;1) translocated to the plasma membrane of HUVEC upon FGF-2 stimulation (<xref ref-type="supplementary-material" rid="pone.0008285.s003">Figure S3</xref>). Treatment of cells with wortmannin completely blocked this translocation (<xref ref-type="supplementary-material" rid="pone.0008285.s003">Figure S3</xref>), suggesting that binding of PLC&#x003b3;1 PH domain to the FGF-2-dependent pool of PtdIns-3,4,5-P<sub>3</sub> is responsible for translocation to the plasma membrane and subsequent activation of the enzyme. Taken together these data indicate that FGF-2 is able to activate PLC&#x003b3;1 in ECs and that PI3K is required for full activation of the enzyme. In contrast the VEGF-dependent activation of PLC&#x003b3;1 was not dependent on PI3K activity (<xref ref-type="supplementary-material" rid="pone.0008285.s004">Figure S4</xref>).</p><fig id="pone-0008285-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g002</object-id><label>Figure 2</label><caption><title>FGF-2 activates PLC&#x003b3;1 in a mechanism involving PI3K activation.</title><p>(A) HUVEC were labelled with &#x0005b;<sup>3</sup>H&#x0005d;myo inositol for 24 h and then pre-treated with 10 &#x000b5;M LY294002 for 15 min before stimulation with 100 ng/ml FGF-2. Data indicate the total amount of inositol phosphates generated at the indicated times and are expressed as percentages of the basal inositol phosphates. Data are means&#x000b1;SEM of values obtained from 9 independent experiments. &#x0002a;p&#x0003c;0.05. (B) Calcium release from serum starved HUVEC untreated or treated with 10 &#x000b5;M LY294002. Cells were stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times (arrows). Data are mean of values obtained from 2 independent experiments.</p></caption><graphic xlink:href="pone.0008285.g002"/></fig></sec><sec id="s3c"><title>FGF-2 activates PI3K in ECs</title><p>To analyze in greater detail FGF-2-mediated PI3K activation in HUVEC, we performed a time course analysis of PtdIns-3,4,5-P<sub>3</sub> production <italic>in vivo</italic> by using TLC analysis of phospholipids extracted from &#x0005b;<sup>32</sup>P&#x0005d;-labelled HUVEC stimulated with FGF-2 for different times. The data indicate that FGF-2 generated PtdIns-3,4,5-P<sub>3</sub> with a peak at 5 and 10 min of stimulation (<xref ref-type="fig" rid="pone-0008285-g003">Figure 3A</xref>). Confocal microscopy analysis using a specific anti PtdIns-3,4,5-P<sub>3</sub> antibody confirmed the FGF-2-induced production of this phosphoinositide at the plasma membrane of HUVEC (<xref ref-type="fig" rid="pone-0008285-g003">Figure 3B</xref>). These data indicate that FGF-2 rapidly and transiently activates PI3K in HUVEC.</p><fig id="pone-0008285-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g003</object-id><label>Figure 3</label><caption><title>FGF-2 activates PI3K in HUVEC.</title><p>(A) TLC analysis of phospholipids extracted from &#x0005b;<sup>32</sup>P&#x0005d;-labelled HUVEC stimulated with 100 ng/ml FGF-2 for the indicated times or 1 &#x000b5;M sphingosine-1-phosphate (S1P) for 5 min. Arrow indicates the PtdIns-3,4,5-P<sub>3</sub> spot. (B) HUVEC grown on glass coverslips were incubated overnight in M199&#x0002b;0.5&#x00025;FBS before stimulation with 100 ng/ml FGF-2 for the indicated times. Coverslips were then incubated with an anti PtdIns-3,4,5-P<sub>3</sub> antibody and analyzed by confocal microscopy. Arrows indicate the plasma membrane localization of the phosphoinositide. Bar&#x0200a;&#x0003d;&#x0200a;10 &#x000b5;m.</p></caption><graphic xlink:href="pone.0008285.g003"/></fig></sec><sec id="s3d"><title>PLC&#x003b3;1 is necessary for FGF-2-dependent migration and capillary tubule formation by ECs</title><p>The results so far indicated that FGF-2 can activate PLC&#x003b3;1 in HUVEC and that PI3K activation is required for full activation of the enzyme. Since we have reported that the PI3K-dependent activation of PLC&#x003b3;1 is a key event in migration of breast cancer cells <xref ref-type="bibr" rid="pone.0008285-Piccolo1">&#x0005b;29&#x0005d;</xref> and PLC&#x003b3;1 is necessary for breast cancer migration and invasion <xref ref-type="bibr" rid="pone.0008285-Sala1">&#x0005b;30&#x0005d;</xref>, we investigated whether this novel PI3K/PLC&#x003b3;1 pathway was involved in the FGF-2-dependent migration of HUVEC. We have already reported that PI3K is required in such process <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref>. To test the role of PLC&#x003b3;1 we first examined the effect of the PLC inhibitor U73122 on cell migration. Transwell assays revealed that blockade of PLC activity completely abrogated the FGF-2-induced migration in HUVEC whereas no significant effect was observed when cells were treated with the inactive structural analogue U73343 (<xref ref-type="fig" rid="pone-0008285-g004">Figure 4A</xref>). Moreover, downregulation of PLC&#x003b3;1 using siRNA specifically inhibited FGF-2-dependent migration of HUVEC (<xref ref-type="fig" rid="pone-0008285-g004">Figure 4B</xref>). These data indicate that the PI3K/PLC&#x003b3;1 pathway is involved in FGF-2-induced cell migration.</p><fig id="pone-0008285-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g004</object-id><label>Figure 4</label><caption><title>PLC&#x003b3;1 is required for FGF-2-induced cell migration.</title><p>(A) HUVEC were incubated overnight in M199&#x0002b;0.5&#x00025;FBS before treatment with 5 &#x000b5;M U73122 or U73343 for 30 min. Migration of cells in the presence of 100 ng/ml FGF-2 was assessed by Transwell assays. Data are means&#x000b1;SEM of values obtained from 7 independent experiments and are expressed as percentage of cells migrating in the absence of FGF-2 (control) &#x0002a;&#x0002a;&#x0002a;p&#x0003c;0.001. (B) HUVEC were transfected with scrambled siRNA or siRNA to downregulate PLC&#x003b3;1 expression. After 24 h cells were incubated overnight in M199&#x0002b;0.5&#x00025; FBS. Migration of cells in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are means&#x000b1;SEM of values obtained from 7-10 independent experiments &#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0008285.g004"/></fig><p>Since migration is a key step in angiogenesis, we then tested whether PLC&#x003b3;1 was involved in this process by performing <italic>in vitro</italic> angiogenesis assays. Capillary tubule formation assay on Matrigel revealed that treatment of HUVEC with the PLC inhibitor U73122 completely blocked the formation of three-dimensional structures whereas U73343 had no effect (<xref ref-type="fig" rid="pone-0008285-g005">Figure 5A</xref>). Similar results were obtained upon PLC&#x003b3;1 downregulation in HUVEC (<xref ref-type="fig" rid="pone-0008285-g005">Figure 5B</xref>). These data indicate that PLC&#x003b3;1 plays a key role in FGF-2-dependent EC remodelling and angiogenesis, most likely by regulating cell migration.</p><fig id="pone-0008285-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g005</object-id><label>Figure 5</label><caption><title>PLC&#x003b3;1 is necessary for FGF-2-induced tubulogenesis <italic>in vitro</italic>.</title><p>(A) Representative images of HUVEC on Matrigel in the absence or presence of FGF-2 plus 2 &#x000b5;M of the PLC inhibitor U73122 or its inactive analogue U73343. Plot represents a quantitative analysis of the experiments obtained by counting the number of branch points from five fields. Data are means&#x000b1;SEM of values obtained from 12 independent experiments.&#x0002a;&#x0002a;p&#x0003c;0.01. NS&#x0200a;&#x0003d;&#x0200a;not significant. (B) Representative images of HUVEC transfected with the scrambled siRNA or siRNA targeting PLC&#x003b3;1 on Matrigel in the presence of FGF-2. Quantitative analysis show data as means&#x000b1;SEM of values obtained from 5 independent experiments. NS&#x0200a;&#x0003d;&#x0200a;not significant.</p></caption><graphic xlink:href="pone.0008285.g005"/></fig></sec><sec id="s3e"><title>PLC&#x003b3;1 mediates Akt phosphorylation through PKC&#x003b1; activation</title><p>We recently demonstrated that FGF-2-dependent migration and tubulogenesis requires activation of the PI3K target PKB/Akt <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref>. The observation that blockade of PLC&#x003b3;1 was able to inhibit both processes prompted us to investigate whether a PLC&#x003b3;1-dependent mechanism was involved in Akt activation. This hypothesis was further supported by recent data demonstrating that PKC&#x003b1; is involved in Akt activation in ECs <xref ref-type="bibr" rid="pone.0008285-Gliki1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Partovian1">&#x0005b;32&#x0005d;</xref>. Since PLC&#x003b3;1 mediates PKC&#x003b1; activation, we investigated whether PLC&#x003b3;1-mediated PKC&#x003b1; activation was required for FGF-2-dependent Akt activation. Blockade of PLC activity inhibited FGF-2-induced phosphorylation of Akt at residue Ser473 in HUVEC (<xref ref-type="fig" rid="pone-0008285-g006">Figure 6A</xref>). No effect was observed with the inactive analogue U73343 (<xref ref-type="fig" rid="pone-0008285-g006">Figure 6A</xref>). Furthermore we observed that treatment of cells with the conventional PKC inhibitor G&#x000f6;6976 (<xref ref-type="fig" rid="pone-0008285-g006">Figure 6B</xref>) and specific PKC&#x003b1; knock down (<xref ref-type="fig" rid="pone-0008285-g006">Figure 6C</xref>) markedly inhibited the FGF-2-mediated Akt phosphorylation, indicating that a PLC&#x003b3;1-mediated PKC&#x003b1; activation is necessary for FGF-2-mediated Akt activation. Taken together these data indicate that FGF-2-induced, PI3K-mediated Akt phosphorylation at residue Ser473 depends on PLC&#x003b3;1 activation and subsequent activation of PKC&#x003b1;.</p><fig id="pone-0008285-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g006</object-id><label>Figure 6</label><caption><title>PLC&#x003b3;1-dependent PKC&#x003b1; activation mediates FGF-2-induced Akt activation.</title><p>HUVEC were incubated overnight in M199&#x0002b;0.5&#x00025;FBS and then treated with the indicated concentrations of U73122 or U73343 for 30 min (A) or 10 &#x000b5;M of the conventional PKCs inhibitor G&#x000f6;6976 (B) before stimulation with 100 ng/ml FGF-2 for 10 min. (C) HUVEC were transfected with scrambled siRNA or siRNAs targeting PKC&#x003b1;. After 24 h cells were serum deprived overnight and then stimulated with 100 ng/ml FGF-2 for the indicated times. Phosphorylation of Akt at Ser473 was assessed by using a specific antibody. Membranes were then stripped and re-probed with an anti Akt. Blots are representative of 7 (A) and 3 (B,C) independent experiments. In all cases, quantitative analysis of the band intensities was performed. Data represent values of pSer473 Akt/Akt expressed as fold increase over control.</p></caption><graphic xlink:href="pone.0008285.g006"/></fig></sec><sec id="s3f"><title>PKC&#x003b1; is required for FGF-2-dependent migration</title><p>We next investigated the role of PKC&#x003b1; in Akt-dependent cellular functions. In particular, since we observed that both PLC&#x003b3;1 and Akt are required for FGF-2-dependent migration, we investigated whether PKC&#x003b1; was also involved in this process. Transwell assays revealed that PKC inhibition with G&#x000f6;6976 (<xref ref-type="fig" rid="pone-0008285-g007">Figure 7A</xref>) completely blocked FGF-2-dependent migration of HUVEC. Consistent with our previous work demonstrating the role of Akt in FGF-2-induced migration of HUVEC <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref> we found that the Akt inhibitor SH5 strongly impaired cell migration (<xref ref-type="fig" rid="pone-0008285-g007">Figure 7A</xref>) whereas no effect was observed using MEK inhibitors (<xref ref-type="fig" rid="pone-0008285-g007">Figure 7A</xref>). Specific PKC&#x003b1; knock down also resulted in complete inhibition of FGF-2-mediated cells migration (<xref ref-type="fig" rid="pone-0008285-g007">Figure 7B</xref>). These data indicate that the novel PI3K/PLC&#x003b3;1/PKC&#x003b1;/Akt pathway is involved in FGF-2-stimulated EC migration.</p><fig id="pone-0008285-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0008285.g007</object-id><label>Figure 7</label><caption><title>PKC&#x003b1; is required for FGF-2-induced cell migration.</title><p>(A) HUVEC were incubated overnight in M199&#x0002b;0.5&#x00025;FBS before treatment with 2 &#x000b5;M G&#x000f6;6796, 50 &#x000b5;M or 10 &#x000b5;M of the MEK inhibitors PD98059 and U0126 respectively or 50 &#x000b5;M of the Akt inhibitor SH5 for 30 min. Migration of cells in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are means&#x000b1;SEM of values obtained from 2-7 independent experiments &#x0002a;p&#x0003c;0.05, &#x0002a;&#x0002a;p&#x0003c;0.01. (B) HUVEC were transfected with scrambled siRNA or siRNA to downregulate PKC&#x003b1; expression. After 24 h cells were incubated overnight in M199&#x0002b;0.5&#x00025; FBS. Migration of cells in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are means&#x000b1;SEM of values obtained from 5 independent experiments &#x0002a;&#x0002a;p&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0008285.g007"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Here we show that PLC&#x003b3;1 is activated upon FGF-2 stimulation in HUVEC and that upstream activation of PI3K is required for full activation of the enzyme. PLC&#x003b3;1 activation is necessary for FGF-2-induced capillary tube formation <italic>in vitro</italic>. This process is the result of distinct intracellular events (cell proliferation, apoptosis, migration) and our data indicate that the role of PLC&#x003b3;1 in tubulogenesis is associated with its role in cell migration.</p><p>The mechanisms of FGF-dependent activation of PI3K and PLC&#x003b3;1 have been controversial. Early studies showed that p85, the regulatory subunit of PI3K, did not coimmunoprecipitate with FGFR1 and no PI3K activity was detected in anti FGFR1 immunoprecipitates <xref ref-type="bibr" rid="pone.0008285-Mohammadi1">&#x0005b;33&#x0005d;</xref>. However, subsequent work revealed that FGF-2 increases PI3K activity in anti-p85 or anti-p110 immunoprecipitates <xref ref-type="bibr" rid="pone.0008285-Mochizuki1">&#x0005b;34&#x0005d;</xref> and that assembly of a multi-docking protein complex is necessary for the FGF-2-mediated activation of PI3K <xref ref-type="bibr" rid="pone.0008285-Ong1">&#x0005b;17&#x0005d;</xref>. By directly monitoring generation of its lipid product PtdIns-3,4,5-P<sub>3</sub>, we demonstrate here that FGF-2 activates PI3K in HUVECs and that this enzyme is involved in PLC&#x003b3;1 activation. Although FGF-induced PLC&#x003b3;1 phosphorylation and activation were previously observed and characterised in fibroblasts and in cell lines overexpressing FGFR1 <xref ref-type="bibr" rid="pone.0008285-Burgess1">&#x0005b;35&#x0005d;</xref>, other studies reported that FGF was not able to induce PLC&#x003b3;1 tyrosine phosphorylation and activation in choroidal ECs <xref ref-type="bibr" rid="pone.0008285-McLaughlin1">&#x0005b;36&#x0005d;</xref>. Similarly, no tyrosine phosphorylation of PLC&#x003b3;1 was detected in FGF-stimulated HUVEC <xref ref-type="bibr" rid="pone.0008285-Wu1">&#x0005b;37&#x0005d;</xref>, although total inositol phosphates production was not monitored in this study. Here we demonstrate that FGF-2 is indeed able to stimulate PLC activity. Moreover selective downregulation of PLC&#x003b3;1 reveals the specific activation of this isoform upon FGF-2 stimulation, in agreement with the reported FGF-2-dependent PLC&#x003b3;1 activation in corneal ECs <xref ref-type="bibr" rid="pone.0008285-Lee1">&#x0005b;38&#x0005d;</xref>. Although the time course of stimulation performed in the previous report was different compared to our study, it is interesting to notice that the fold increase of total inositol phosphates accumulation upon 1 h of FGF-2 stimulation is very similar between the two studies. We further show that downregulation of PLC&#x003b3;1 does not affect the expression levels of the related PLC isoform PLC&#x003b3;2. Interestingly, downregulation of PLC&#x003b3;2 but not PLC&#x003b3;1 specifically reduces the number of cells compared to HUVECs expressing a scrambled siRNA, suggesting a potential role for PLC&#x003b3;2 in proliferation and/or survival of cells. These results are consistent with accumulating evidence revealing distinct, not overlapping functions for PLC&#x003b3;1 and PLC&#x003b3;2 <xref ref-type="bibr" rid="pone.0008285-Wilde1">&#x0005b;39&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0008285-Mao1">&#x0005b;42&#x0005d;</xref>.</p><p>Our study indicates that PI3K activation is required for PLC&#x003b3;1 activation, consistent with our previous work describing the interaction of PLC&#x003b3;1 PH domain with the PI3K product PtdIns-3,4,5-P<sub>3</sub> and its role in membrane targeting of the enzyme <xref ref-type="bibr" rid="pone.0008285-Falasca1">&#x0005b;24&#x0005d;</xref> and with evidence indicating that tyrosine phosphorylation is not sufficient for PLC&#x003b3;1 activity <xref ref-type="bibr" rid="pone.0008285-Maffucci4">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Rhee1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Sekiya1">&#x0005b;44&#x0005d;</xref>. Our data clearly indicate that monitoring PLC&#x003b3;1 activation only by analysing its tyrosine phosphorylation does not take into account the possibility of additional and/or alternative mechanisms of activation of the enzyme <xref ref-type="bibr" rid="pone.0008285-Maffucci4">&#x0005b;28&#x0005d;</xref>. In this respect it must be observed that, although no activation of PLC&#x003b3;1 was detected in porcine aortic ECs overexpressing a mutant FGFR1 unable to induce tyrosine phosphorylation of PLC&#x003b3;1 (FGFR1 Y766F) <xref ref-type="bibr" rid="pone.0008285-Landgren1">&#x0005b;45&#x0005d;</xref>, a detailed analysis of PLC&#x003b3;1 activation at different times of stimulation was not performed in this report. Indeed by performing accurate time course experiments we observed that at specific time points a PI3K-dependent PLC activity can be detected in cell lines overexpressing the FGFR1 Y766F mutant (data not shown). It must be noted that PI3K is involved in FGF-2-dependent but not in VEGF-dependent PLC&#x003b3;1 activation suggesting that different mechanisms of PLC&#x003b3;1 activation exist in different cellular contexts.</p><p>We further show that the PI3K-dependent PLC&#x003b3;1 activation is required for FGF-2-dependent migration of HUVEC. Previous data indicated that PLC&#x003b3;1 was not required for migration downstream of FGFR1 activation <xref ref-type="bibr" rid="pone.0008285-Landgren1">&#x0005b;45&#x0005d;</xref> but it must be noted that these data were obtained in cells overexpressing the FGFR1 Y766F mutant therefore in the absence of PLC&#x003b3;1 tyrosine phosphorylation. Since these cells were still able to migrate in response to FGFR1 activation it was concluded that PLC&#x003b3;1 had no role in this process <xref ref-type="bibr" rid="pone.0008285-Landgren1">&#x0005b;45&#x0005d;</xref>. However, as discussed above, such a conclusion did not take into account the possibility of the PI3K-mediated activation of PLC&#x003b3;1. The role of PLC&#x003b3;1 in EC migration is consistent with the reported role of this enzyme in cell migration, invasion and spreading of other cell types <xref ref-type="bibr" rid="pone.0008285-Price1">&#x0005b;46&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0008285-Jones1">&#x0005b;49&#x0005d;</xref>. In particular we demonstrated that PI3K-mediated PLC&#x003b3;1 activation is required for epidermal growth factor-induced migration of breast cancer cells <xref ref-type="bibr" rid="pone.0008285-Piccolo1">&#x0005b;29&#x0005d;</xref>. More recently, we reported that PLC&#x003b3;1 is required for breast cancer cells migration and invasion <xref ref-type="bibr" rid="pone.0008285-Sala1">&#x0005b;30&#x0005d;</xref>. Our present and previous data indicate that both PI3K <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref> and PLC&#x003b3;1 are required for FGF-2-induced tubulogenesis <italic>in vitro</italic>. Recent data have suggested that PI3K and PLC&#x003b3;1 have opposite effects on capillary tube formation <italic>in vitro</italic> with PI3K promoting tubule formation and PLC&#x003b3;1 regulating tubule regression <xref ref-type="bibr" rid="pone.0008285-Im1">&#x0005b;50&#x0005d;</xref>. The apparent discrepancies between this report and our present data are likely due to the different experimental conditions. Furthermore, our results are in agreement with data demonstrating the key role of PLC&#x003b3;1 in HUVEC cell elongation and network formation on Matrigel <xref ref-type="bibr" rid="pone.0008285-Jones1">&#x0005b;49&#x0005d;</xref>. Our data reveal that the FGF-2-induced tubule formation is also dependent on PLC&#x003b3;1 activation. It must be pointed out that we cannot completely rule out the possibility that in our experimental conditions the detected tubule formation is not directly dependent on FGF-2 stimulation. The possibility exists that FGF-2 stimulation of HUVEC upon overnight serum starvation induces survival of cells which are then able to migrate in response to extracellular matrix components, as previously reported <xref ref-type="bibr" rid="pone.0008285-Jones1">&#x0005b;49&#x0005d;</xref>. Nevertheless our data indicate the key role of PLC&#x003b3;1 in this process, suggesting that activation of a PI3K/PLC&#x003b3;1 pathway is involved in FGF-2-dependent angiogenesis. This would be consistent with recent data in literature. Indeed it has been reported that y10 (the zebra fish homologue of PLC&#x003b3;1) mutant embryos display specific defect in the formation of arteries, but not veins <xref ref-type="bibr" rid="pone.0008285-Lawson1">&#x0005b;23&#x0005d;</xref>. Sequence analysis revealed that the majority of the mutations in y10 mutants occur in the PH domain <xref ref-type="bibr" rid="pone.0008285-Lawson1">&#x0005b;23&#x0005d;</xref> and in particular in the &#x003b2;3/&#x003b2;4 region of the PH domain that we demonstrated to be important for PtdIns-3,4,5-P<sub>3</sub> binding and growth factor-induced membrane localization of PLC&#x003b3;1 <xref ref-type="bibr" rid="pone.0008285-Falasca1">&#x0005b;24&#x0005d;</xref>. These data suggest that a PI3K-dependent regulation of PLC&#x003b3;1 might be involved in vasculogenesis.</p><p>In an effort to define the mechanism of PLC&#x003b3;1-dependent regulation of EC tubulogenesis we found that activation of a PLC&#x003b3;1/PKC&#x003b1; pathway is necessary for FGF-2-induced Akt phosphorylation. Akt is involved in physiological and pathological angiogenesis through effects in both EC and cells producing endothelial signals such as tumour cells <xref ref-type="bibr" rid="pone.0008285-Manning1">&#x0005b;51&#x0005d;</xref>-<xref ref-type="bibr" rid="pone.0008285-Gordan1">&#x0005b;55&#x0005d;</xref>. Furthermore Akt is required for EC migration <xref ref-type="bibr" rid="pone.0008285-Ackah1">&#x0005b;56&#x0005d;</xref> and we reported that this enzyme is necessary for both FGF-2-induced migration and tubulogenesis in HUVEC <xref ref-type="bibr" rid="pone.0008285-Maffucci3">&#x0005b;27&#x0005d;</xref>. Akt activation requires its phosphorylation at Thr308 by phosphoinositide-dependent kinase-1 <xref ref-type="bibr" rid="pone.0008285-Alessi1">&#x0005b;57&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Stephens1">&#x0005b;58&#x0005d;</xref> and at Ser473. Although the mTORC2 complex, containing the enzyme mammalian target of rapamycin, has been shown to mediate Ser473 phosphorylation in several cell types <xref ref-type="bibr" rid="pone.0008285-Sarbassov1">&#x0005b;59&#x0005d;</xref>, the precise mechanism of Akt Ser473 phosphorylation and the link between PI3K and this crucial event in Akt activation remains unclear. Our data here reveal a novel and critical role for a PLC&#x003b3;1/PKC&#x003b1; pathway in mediating FGF stimulation of Akt phosphorylation at Ser473. This data is consistent with previous reports indicating a role for PKC in Akt phosphorylation in ECs <xref ref-type="bibr" rid="pone.0008285-Gliki1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0008285-Partovian1">&#x0005b;32&#x0005d;</xref>. Interestingly it was recently reported that a PLC&#x003b3;1-dependent PKC activation is necessary for Akt phosphorylation at Ser473 in monocytes stimulated with phospholipase A<sub>2</sub>-modified low density lipoprotein <xref ref-type="bibr" rid="pone.0008285-Preiss1">&#x0005b;60&#x0005d;</xref>. On the other hand, we did not detect impairment of Ser473 Akt phosphorylation in breast cancer cells stimulated with epidermal growth factor upon downregulation of PLC&#x003b3;1 <xref ref-type="bibr" rid="pone.0008285-Sala1">&#x0005b;30&#x0005d;</xref> suggesting that the role of PLC&#x003b3;1 in mediating Akt phosphorylation may be cell and stimulus specific. Due to the variety of intracellular events requiring Akt activation it is likely that identification of PLC&#x003b3;1 as a key mediator in its activation will lead to the discovery of novel roles for PLC&#x003b3;1 in different intracellular functions.</p><p>EC lining the lumen of all blood vessels play essential roles in maintaining normal vascular function and in vascular homeostasis <xref ref-type="bibr" rid="pone.0008285-Carmeliet1">&#x0005b;1&#x0005d;</xref>. EC migration is a crucial step in angiogenesis and is essential for regeneration of endothelia damaged by balloon catheter angioplasty and stent placement. Furthermore EC migration is a prerequisite for the formation of collateral blood vessels in ischaemic heart and peripheral vascular disease <xref ref-type="bibr" rid="pone.0008285-Carmeliet1">&#x0005b;1&#x0005d;</xref>. A better understanding of the factors and intracellular processes governing EC migration will have profound implications not only for cardiovascular disease but also for a better understanding of embryogenesis and reproduction. Furthermore due to the emerging role of FGF-2 in tumour angiogenesis and its potential role in drug resistance to anti-angiogenic agents, understanding the FGF-dependent signalling pathways will prove useful to design novel potential strategies of intervention. In this respect our present data, together with our previous work indicating the critical role of PLC&#x003b3;1 in metastasis development and progression <xref ref-type="bibr" rid="pone.0008285-Sala1">&#x0005b;30&#x0005d;</xref> suggest that targeting PLC&#x003b3;1 may represent a useful strategy to inhibit metastasis growth and possibly tumour angiogenesis simultaneously. In this respect identification of PLC&#x003b3;1 as a critical player in regulation of FGF-induced EC migration and tubulogenesis and in modulating Akt activation will have both biological and potential therapeutic implications.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0008285.s001"><label>Figure S1</label><caption><p>Effects of downregulation of PLC&#x003b3;1 and PLC&#x003b3;2 on HUVEC. (A) Expression levels of PLC&#x003b3;1 or PLC&#x003b3;2 in HUVEC transfected with the indicated siRNAs. Equal loading was confirmed using anti Akt or anti ERK antibodies. (B) HUVEC were transfected with scrambled siRNA or siRNAs targeting PLC&#x003b3;1 or PLC&#x003b3;2. After 24 h, cells were starved overnight in M199&#x0002b;0.5&#x00025; FBS and then the number of cells was determined by manual counting. Data are expressed as percentage of cells transfected with scrambled siRNA and are means&#x000b1;SEM of values obtained from 5 independent experiments. &#x0002a;p&#x0003c;0.05, &#x0002a;&#x0002a;p&#x0003c;0.01 vs HUVEC expressing siRNA PLC&#x003b3;1. In these experiments siRNA targeting PLC&#x003b3;2 was from Qiagen.</p><p>(1.56 MB TIF)</p></caption><media xlink:href="pone.0008285.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0008285.s002"><label>Figure S2</label><caption><p>FGF-2 activates PLC&#x003b3;1 in a mechanism involving PI3K activation. HUVEC were labelled with &#x0005b;3H&#x0005d;myo inositol for 24 h and then pre-treated with 100 nM wortmannin for 15 min before stimulation with 100 ng/ml FGF-2. Data indicate the total amount of inositol phosphates generated at the indicated times and are expressed as percentages of the basal inositol phosphates. Data are means&#x000b1;SEM of values obtained from 1&#x02013;2 independent experiments.</p><p>(3.73 MB TIF)</p></caption><media xlink:href="pone.0008285.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0008285.s003"><label>Figure S3</label><caption><p>PI3K regulates FGF-2-induced PLC&#x003b3;1 recruitment to the plasma membrane. HUVEC were transfected with a GFP-tagged PLC&#x003b3;1 PH domain and plated on glass coverslips. After 24 h cells were serum deprived overnight in M199&#x0002b;0.5&#x00025; FBS and then left untreated or pre-treated with 100 nM wortmannin for 15 min before stimulation with 100 ng/ml FGF-2 for 10 min. Coverslips were fixed and analyzed by confocal microscopy.</p><p>(6.24 MB TIF)</p></caption><media xlink:href="pone.0008285.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0008285.s004"><label>Figure S4</label><caption><p>VEGF-mediated activation of PLC&#x003b3;1 is not dependent on PI3K activation. HUVEC were labelled with &#x0005b;3H&#x0005d;myo inositol for 24 h and then pre-treated with 10 &#x000b5;M LY294002 (A) or 100 nM wortmannin (B) for 15 min before stimulation with 10 ng/ml VEGF. Data indicate the total amount of inositol phosphates generated at the indicated times and are expressed as percentages of the basal inositol phosphates. Data are means&#x000b1;SEM of values obtained from 1&#x02013;3 (A) or 1&#x02013;4 independent experiments (B).</p><p>(6.07 MB TIF)</p></caption><media xlink:href="pone.0008285.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0008285-Carmeliet1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>Angiogenesis in health and disease.</article-title><source>Nat Med</source><volume>9</volume><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">12778163</pub-id></mixed-citation></ref><ref id="pone.0008285-Risau1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risau</surname><given-names>W</given-names></name></person-group><year>1997</year><article-title>Mechanisms of angiogenesis.</article-title><source>Nature</source><volume>386</volume><fpage>671</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">9109485</pub-id></mixed-citation></ref><ref id="pone.0008285-Ferrara1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Davis-Smyth</surname><given-names>T</given-names></name></person-group><year>1997</year><article-title>The biology of vascular endothelial growth factor.</article-title><source>Endocr Rev</source><volume>18</volume><fpage>4</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9034784</pub-id></mixed-citation></ref><ref id="pone.0008285-CrossM1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross M</surname><given-names>J</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><year>2001</year><article-title>FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.</article-title><source>Trends Pharmacol Sci</source><volume>22</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">11282421</pub-id></mixed-citation></ref><ref id="pone.0008285-Carmeliet2"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2000</year><article-title>Angiogenesis in cancer and other diseases.</article-title><source>Nature</source><volume>407</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">11001068</pub-id></mixed-citation></ref><ref id="pone.0008285-Ferrara2"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Kerbel</surname><given-names>RS</given-names></name></person-group><year>2005</year><article-title>Angiogenesis as a therapeutic target.</article-title><source>Nature</source><volume>438</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">16355214</pub-id></mixed-citation></ref><ref id="pone.0008285-Eswarakumar1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Cellular signalling by fibroblast growth factor receptor.</article-title><source>Cytokine Growth Factor Rev</source><volume>16</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">15863030</pub-id></mixed-citation></ref><ref id="pone.0008285-Cao1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Hedlund</surname><given-names>E-M</given-names></name></person-group><year>2008</year><article-title>R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathway.</article-title><source>J Mol Med</source><volume>86</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">18392794</pub-id></mixed-citation></ref><ref id="pone.0008285-Soutter1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soutter</surname><given-names>AD</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>1993</year><article-title>Basic fibroblast growth factor secreted by an animal tumor is detectable n urine.</article-title><source>Cancer Res</source><volume>53</volume><fpage>5297</fpage><lpage>5299</lpage><pub-id pub-id-type="pmid">8221664</pub-id></mixed-citation></ref><ref id="pone.0008285-Malek1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malek</surname><given-names>AM</given-names></name><name><surname>Connors</surname><given-names>S</given-names></name><name><surname>Robertson</surname><given-names>RL</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>RM</given-names></name></person-group><year>1997</year><article-title>Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders.</article-title><source>Pediatr Neurosurg</source><volume>27</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">9577971</pub-id></mixed-citation></ref><ref id="pone.0008285-Nguyen1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Budson</surname><given-names>AE</given-names></name><name><surname>Richie</surname><given-names>JP</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><etal/></person-group><year>1994</year><article-title>Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer.</article-title><source>J Natl Cancer Inst</source><volume>86</volume><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">7508518</pub-id></mixed-citation></ref><ref id="pone.0008285-Nissen1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>LJ</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Hedlund</surname><given-names>E-M</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><year>2007</year><article-title>Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularisation and metastasis.</article-title><source>J Clin Invest</source><volume>117</volume><fpage>2766</fpage><lpage>2777</lpage><pub-id pub-id-type="pmid">17909625</pub-id></mixed-citation></ref><ref id="pone.0008285-Casanovas1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanovas</surname><given-names>O</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Bergers</surname><given-names>G</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.</article-title><source>Cancer Cell</source><volume>8</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">16226705</pub-id></mixed-citation></ref><ref id="pone.0008285-Beenken1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beenken</surname><given-names>A</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>The FGF family: biology, pathophysiology and therapy.</article-title><source>Nat Rev Drug Discov</source><volume>8</volume><fpage>235</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">19247306</pub-id></mixed-citation></ref><ref id="pone.0008285-Maffucci1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffucci</surname><given-names>T</given-names></name><name><surname>Falasca</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide-protein co-operative mechanism.</article-title><source>FEBS Lett</source><volume>506</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">11602240</pub-id></mixed-citation></ref><ref id="pone.0008285-Jiang1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Zheng</surname><given-names>JZ</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><year>2000</year><article-title>Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>1749</fpage><lpage>1753</lpage><pub-id pub-id-type="pmid">10677529</pub-id></mixed-citation></ref><ref id="pone.0008285-Ong1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>SH</given-names></name><name><surname>Hadari</surname><given-names>YR</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Guy</surname><given-names>GR</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>6074</fpage><lpage>6079</lpage><pub-id pub-id-type="pmid">11353842</pub-id></mixed-citation></ref><ref id="pone.0008285-Divecha1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divecha</surname><given-names>N</given-names></name><name><surname>Irvine</surname><given-names>RF</given-names></name></person-group><year>1995</year><article-title>Phospholipid signaling.</article-title><source>Cell</source><volume>80</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">7834746</pub-id></mixed-citation></ref><ref id="pone.0008285-Rahimi1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname><given-names>N</given-names></name><name><surname>Dayanir</surname><given-names>V</given-names></name><name><surname>Lashkari</surname><given-names>K</given-names></name></person-group><year>2000</year><article-title>Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>16986</fpage><lpage>16992</lpage><pub-id pub-id-type="pmid">10747927</pub-id></mixed-citation></ref><ref id="pone.0008285-Takahashi1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Chida</surname><given-names>K</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.</article-title><source>EMBO J</source><volume>20</volume><fpage>2768</fpage><lpage>2778</lpage><pub-id pub-id-type="pmid">11387210</pub-id></mixed-citation></ref><ref id="pone.0008285-Meyer1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>RD</given-names></name><name><surname>Latz</surname><given-names>C</given-names></name><name><surname>Rahimi</surname><given-names>N</given-names></name></person-group><year>2003</year><article-title>Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>16347</fpage><lpage>16355</lpage><pub-id pub-id-type="pmid">12598525</pub-id></mixed-citation></ref><ref id="pone.0008285-Liao1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>HJ</given-names></name><name><surname>Kume</surname><given-names>T</given-names></name><name><surname>McKay</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Ihle</surname><given-names>JN</given-names></name><etal/></person-group><year>2002</year><article-title>Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>9335</fpage><lpage>9341</lpage><pub-id pub-id-type="pmid">11744703</pub-id></mixed-citation></ref><ref id="pone.0008285-Lawson1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>ND</given-names></name><name><surname>Mugford</surname><given-names>JW</given-names></name><name><surname>Diamond</surname><given-names>BA</given-names></name><name><surname>Weinstein</surname><given-names>BM</given-names></name></person-group><year>2003</year><article-title>Phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development.</article-title><source>Genes Dev</source><volume>17</volume><fpage>1346</fpage><lpage>1351</lpage><pub-id pub-id-type="pmid">12782653</pub-id></mixed-citation></ref><ref id="pone.0008285-Falasca1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falasca</surname><given-names>M</given-names></name><name><surname>Logan</surname><given-names>SK</given-names></name><name><surname>Lehto</surname><given-names>VP</given-names></name><name><surname>Baccante</surname><given-names>G</given-names></name><name><surname>Lemmon</surname><given-names>MA</given-names></name><etal/></person-group><year>1998</year><article-title>Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting.</article-title><source>EMBO J</source><volume>17</volume><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">9430633</pub-id></mixed-citation></ref><ref id="pone.0008285-Ear1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ear</surname><given-names>T</given-names></name><name><surname>Giguere</surname><given-names>P</given-names></name><name><surname>Fleury</surname><given-names>A</given-names></name><name><surname>Stankova</surname><given-names>J</given-names></name><name><surname>Payet</surname><given-names>MD</given-names></name><etal/></person-group><year>2001</year><article-title>High efficiency transient transfection of genes in human umbilical vein endothelial cells by electroporation.</article-title><source>J Imm Meth</source><volume>257</volume><fpage>41</fpage><lpage>49</lpage></mixed-citation></ref><ref id="pone.0008285-Maffucci2"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffucci</surname><given-names>T</given-names></name><name><surname>Cooke</surname><given-names>FT</given-names></name><name><surname>Foster</surname><given-names>FM</given-names></name><name><surname>Traer</surname><given-names>CJ</given-names></name><name><surname>Fry</surname><given-names>MJ</given-names></name><etal/></person-group><year>2005</year><article-title>Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.</article-title><source>J Cell Biol</source><volume>169</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">15928202</pub-id></mixed-citation></ref><ref id="pone.0008285-Maffucci3"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffucci</surname><given-names>T</given-names></name><name><surname>Piccolo</surname><given-names>E</given-names></name><name><surname>Cumashi</surname><given-names>A</given-names></name><name><surname>Iezzi</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>AM</given-names></name><etal/></person-group><year>2005</year><article-title>Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.</article-title><source>Cancer Res</source><volume>65</volume><fpage>8339</fpage><lpage>8349</lpage><pub-id pub-id-type="pmid">16166311</pub-id></mixed-citation></ref><ref id="pone.0008285-Maffucci4"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffucci</surname><given-names>T</given-names></name><name><surname>Falasca</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma.</article-title><source>Biochem Soc Trans</source><volume>35</volume><fpage>229</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">17371245</pub-id></mixed-citation></ref><ref id="pone.0008285-Piccolo1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>E</given-names></name><name><surname>Innominato</surname><given-names>PF</given-names></name><name><surname>Mariggio</surname><given-names>MA</given-names></name><name><surname>Maffucci</surname><given-names>T</given-names></name><name><surname>Iacobelli</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration.</article-title><source>Oncogene</source><volume>21</volume><fpage>6520</fpage><lpage>6529</lpage><pub-id pub-id-type="pmid">12226755</pub-id></mixed-citation></ref><ref id="pone.0008285-Sala1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>G</given-names></name><name><surname>Dituri</surname><given-names>F</given-names></name><name><surname>Raimondi</surname><given-names>C</given-names></name><name><surname>Previdi</surname><given-names>S</given-names></name><name><surname>Maffucci</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>Phospholipase Cgamma1 is required for metastasis development and progression.</article-title><source>Cancer Res</source><volume>68</volume><fpage>10187</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19074886</pub-id></mixed-citation></ref><ref id="pone.0008285-Gliki1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gliki</surname><given-names>G</given-names></name><name><surname>Wheeler-Jones</surname><given-names>C</given-names></name><name><surname>Zachary</surname><given-names>I</given-names></name></person-group><year>2002</year><article-title>Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3&#x02032;-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis.</article-title><source>Cell Biol Int</source><volume>9</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">12377207</pub-id></mixed-citation></ref><ref id="pone.0008285-Partovian1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partovian</surname><given-names>C</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells.</article-title><source>Cell Signal</source><volume>16</volume><fpage>951</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">15157674</pub-id></mixed-citation></ref><ref id="pone.0008285-Mohammadi1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name><name><surname>Sorokin</surname><given-names>A</given-names></name><name><surname>Burgess</surname><given-names>WH</given-names></name><name><surname>Jaye</surname><given-names>M</given-names></name><etal/></person-group><year>1996</year><article-title>Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.</article-title><source>Mol Cell Biol</source><volume>16</volume><fpage>977</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">8622701</pub-id></mixed-citation></ref><ref id="pone.0008285-Mochizuki1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Tsuda</surname><given-names>S</given-names></name><name><surname>Kanetake</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>S</given-names></name></person-group><year>2002</year><article-title>Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase.</article-title><source>Oncogene</source><volume>21</volume><fpage>7027</fpage><lpage>7033</lpage><pub-id pub-id-type="pmid">12370824</pub-id></mixed-citation></ref><ref id="pone.0008285-Burgess1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>WH</given-names></name><name><surname>Dionne</surname><given-names>CA</given-names></name><name><surname>Kaplow</surname><given-names>J</given-names></name><name><surname>Mudd</surname><given-names>R</given-names></name><name><surname>Friesel</surname><given-names>R</given-names></name><etal/></person-group><year>1990</year><article-title>Characterization and cDNA cloning of phospholipase C-gamma, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase.</article-title><source>Mol Cell Biol</source><volume>10</volume><fpage>4770</fpage><lpage>4777</lpage><pub-id pub-id-type="pmid">2167438</pub-id></mixed-citation></ref><ref id="pone.0008285-McLaughlin1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>AP</given-names></name><name><surname>De Vries</surname><given-names>GW</given-names></name></person-group><year>2001</year><article-title>Role of PLCgamma and Ca(2&#x0002b;) in VEGF- and FGF-induced choroidal endothelial cell proliferation.</article-title><source>Am J Physiol Cell Physiol</source><volume>281</volume><fpage>C1448</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">11600407</pub-id></mixed-citation></ref><ref id="pone.0008285-Wu1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LW</given-names></name><name><surname>Mayo</surname><given-names>LD</given-names></name><name><surname>Dunbar</surname><given-names>JD</given-names></name><name><surname>Kessler</surname><given-names>KM</given-names></name><name><surname>Baerwald</surname><given-names>MR</given-names></name><etal/></person-group><year>2000</year><article-title>Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>5096</fpage><lpage>5103</lpage><pub-id pub-id-type="pmid">10671553</pub-id></mixed-citation></ref><ref id="pone.0008285-Lee1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HT</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Kay</surname><given-names>EP</given-names></name></person-group><year>2002</year><article-title>Cdk4 and p27Kip1 play a role in PLC-&#x003b3;1-mediated mitogenic signalling pathway of 18 kDa FGF-2 in corneal endothelial cells.</article-title><source>Mol Vis</source><volume>8</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11889462</pub-id></mixed-citation></ref><ref id="pone.0008285-Wilde1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilde</surname><given-names>JI</given-names></name><name><surname>Watson</surname><given-names>SP</given-names></name></person-group><year>2001</year><article-title>Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other?</article-title><source>Cell Signal</source><volume>13</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">11602179</pub-id></mixed-citation></ref><ref id="pone.0008285-Upshaw1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upshaw</surname><given-names>JL</given-names></name><name><surname>Schoon</surname><given-names>RA</given-names></name><name><surname>Dick</surname><given-names>CJ</given-names></name><name><surname>Billadeau</surname><given-names>DD</given-names></name><name><surname>Leibson</surname><given-names>PJ</given-names></name></person-group><year>2005</year><article-title>The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors.</article-title><source>J Immunol</source><volume>175</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">15972651</pub-id></mixed-citation></ref><ref id="pone.0008285-Regunathan1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regunathan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kutlesa</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><etal/></person-group><year>2006</year><article-title>Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells.</article-title><source>J Immunol</source><volume>177</volume><fpage>5365</fpage><lpage>5376</lpage><pub-id pub-id-type="pmid">17015722</pub-id></mixed-citation></ref><ref id="pone.0008285-Mao1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>D</given-names></name><name><surname>Epple</surname><given-names>H</given-names></name><name><surname>Uthgenannt</surname><given-names>B</given-names></name><name><surname>Novack</surname><given-names>DV</given-names></name><name><surname>Faccio</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2.</article-title><source>J Clin Invest</source><volume>116</volume><fpage>2869</fpage><lpage>2879</lpage><pub-id pub-id-type="pmid">17053833</pub-id></mixed-citation></ref><ref id="pone.0008285-Rhee1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SG</given-names></name></person-group><year>2001</year><article-title>Regulation of phosphoinositide-specific phospholipase C.</article-title><source>Annu Rev Biochem</source><volume>70</volume><fpage>281</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">11395409</pub-id></mixed-citation></ref><ref id="pone.0008285-Sekiya1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekiya</surname><given-names>F</given-names></name><name><surname>Poulin</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Rhee</surname><given-names>SG</given-names></name></person-group><year>2004</year><article-title>Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 phosphorylation is not sufficient for lipase activation.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>32181</fpage><lpage>32190</lpage><pub-id pub-id-type="pmid">15161916</pub-id></mixed-citation></ref><ref id="pone.0008285-Landgren1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landgren</surname><given-names>E</given-names></name><name><surname>Klint</surname><given-names>P</given-names></name><name><surname>Yokote</surname><given-names>K</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><year>1998</year><article-title>Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding.</article-title><source>Oncogene</source><volume>17</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9690510</pub-id></mixed-citation></ref><ref id="pone.0008285-Price1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>JT</given-names></name><name><surname>Tiganis</surname><given-names>T</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Djakiew</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name></person-group><year>1999</year><article-title>Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3&#x02032;-kinase and phospholipase C-dependent mechanism.</article-title><source>Cancer Res</source><volume>59</volume><fpage>5475</fpage><lpage>5478</lpage><pub-id pub-id-type="pmid">10554021</pub-id></mixed-citation></ref><ref id="pone.0008285-Thomas1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>SM</given-names></name><name><surname>Coppelli</surname><given-names>FM</given-names></name><name><surname>Wells</surname><given-names>A</given-names></name><name><surname>Gooding</surname><given-names>WE</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Epidermal growth factor receptor-stimulated activation of phospholipase C-&#x003b3;- 1 promotes invasion of head and neck squamous cell carcinoma.</article-title><source>Cancer Res</source><volume>63</volume><fpage>5629</fpage><lpage>5635</lpage><pub-id pub-id-type="pmid">14500405</pub-id></mixed-citation></ref><ref id="pone.0008285-Turner1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>T</given-names></name><name><surname>Epps-Fung</surname><given-names>MV</given-names></name><name><surname>Kassis</surname><given-names>J</given-names></name><name><surname>Wells</surname><given-names>A</given-names></name></person-group><year>1997</year><article-title>Molecular inhibition of phospholipase C gamma signaling abrogates DU-145 prostate tumor cell invasion.</article-title><source>Clin Cancer Res</source><volume>3</volume><fpage>2275</fpage><lpage>2282</lpage><pub-id pub-id-type="pmid">9815625</pub-id></mixed-citation></ref><ref id="pone.0008285-Jones1"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>NP</given-names></name><name><surname>Peak</surname><given-names>J</given-names></name><name><surname>Brader</surname><given-names>S</given-names></name><name><surname>Eccles</surname><given-names>SA</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>PLCgamma1 is essential for early events in integrin signaling required for cell motility.</article-title><source>J Cell Sci</source><volume>118</volume><fpage>2695</fpage><lpage>2706</lpage><pub-id pub-id-type="pmid">15944397</pub-id></mixed-citation></ref><ref id="pone.0008285-Im1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>E</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Regulating angiogenesis at the level of PtdIns-4,5-P2.</article-title><source>EMBO J</source><volume>25</volume><fpage>2075</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">16628216</pub-id></mixed-citation></ref><ref id="pone.0008285-Manning1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year>2007</year><article-title>AKT/PKB signaling: navigating downstream.</article-title><source>Cell</source><volume>129</volume><fpage>1261</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">17604717</pub-id></mixed-citation></ref><ref id="pone.0008285-Olsson1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>AK</given-names></name><name><surname>Dimberg</surname><given-names>A</given-names></name><name><surname>Kreuger</surname><given-names>J</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><year>2006</year><article-title>VEGF receptor signalling - in control of vascular function.</article-title><source>Nat Rev Mol Cell Biol</source><volume>7</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">16633338</pub-id></mixed-citation></ref><ref id="pone.0008285-Dimmeler1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Fleming</surname><given-names>I</given-names></name><name><surname>Fisslthaler</surname><given-names>B</given-names></name><name><surname>Hermann</surname><given-names>C</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name><etal/></person-group><year>1999</year><article-title>Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.</article-title><source>Nature</source><volume>399</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">10376603</pub-id></mixed-citation></ref><ref id="pone.0008285-Fulton1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulton</surname><given-names>D</given-names></name><name><surname>Gratton</surname><given-names>J</given-names></name><name><surname>McCabe</surname><given-names>TJ</given-names></name><name><surname>Fontana</surname><given-names>J</given-names></name><name><surname>Fujio</surname><given-names>Y</given-names></name><etal/></person-group><year>1999</year><article-title>Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.</article-title><source>Nature</source><volume>399</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">10376602</pub-id></mixed-citation></ref><ref id="pone.0008285-Gordan1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordan</surname><given-names>JD</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><year>2007</year><article-title>Hypoxia-inducible factors: central regulators of the tumor phenotype.</article-title><source>Curr Opin Genet Dev</source><volume>17</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">17208433</pub-id></mixed-citation></ref><ref id="pone.0008285-Ackah1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackah</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zoellner</surname><given-names>S</given-names></name><name><surname>Iwakiri</surname><given-names>Y</given-names></name><name><surname>Skurk</surname><given-names>C</given-names></name><etal/></person-group><year>2005</year><article-title>Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>2119</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">16075056</pub-id></mixed-citation></ref><ref id="pone.0008285-Alessi1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Casamayor</surname><given-names>A</given-names></name><name><surname>Caudwell</surname><given-names>FB</given-names></name><name><surname>Morrice</surname><given-names>N</given-names></name><etal/></person-group><year>1997</year><article-title>3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.</article-title><source>Curr Biol</source><volume>7</volume><fpage>776</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">9368760</pub-id></mixed-citation></ref><ref id="pone.0008285-Stephens1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Painter</surname><given-names>GF</given-names></name><etal/></person-group><year>1998</year><article-title>Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.</article-title><source>Science</source><volume>279</volume><fpage>710</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">9445477</pub-id></mixed-citation></ref><ref id="pone.0008285-Sarbassov1"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year>2005</year><article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.</article-title><source>Science</source><volume>307</volume><fpage>1098</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">15718470</pub-id></mixed-citation></ref><ref id="pone.0008285-Preiss1"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preiss</surname><given-names>S</given-names></name><name><surname>Namgaladze</surname><given-names>D</given-names></name><name><surname>Brune</surname><given-names>B</given-names></name></person-group><year>2007</year><article-title>Critical role for classical PKC in activating Akt by phospholipase A2-modified LDL in monocytic cells.</article-title><source>Cardiovasc Res</source><volume>73</volume><fpage>833</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">17261275</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by British Heart Foundation (grant PG/04/033/16906 and grant PG/06/022/20348 to MF). SA-H was supported by British Heart Foundation (grant PG/04/033/16906 to MF). VD was supported by Barts and The London Charity (grant 430/647 to TM). GS was supported by Association for International Cancer Research (grant 05-127 to MF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>